3 models fit Theravance Biopharma Inc. Ordinary Shares and they disagree: 1 of 3 land within 15% of the average.
Two or more of our models back this value.
Near fair value(i)Silver69
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionTheravance Biopharma Inc. Ordinary Shares (TBPH)
Fair value (3 models)
$17.33
ACCE price target
$17.50
Rating
Fairly valued
Horizon
12 months
Fair value published on 16 Oct 2026, 00:00 CEST; previously $17.91 since 11 Oct 2026, 00:00 CEST.
ACCE price target published on 13 Oct 2026, 00:00 CEST.
Rating published on 20 Oct 2026, 15:04 CEST.
Price used: $17.03 at the close on 25 Sept 2026, 22:00 CEST.
Models: Discounted cash flow, Dividend discount, EV/EBITDA comparison, Graham number, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
1.8% below
+1.8% to fair value
ACCE score
58
out of 100
Analysts
50% buy
4 covering
P/E
16.4x
forward 9.7x
1-year return
+23.5%
Dividend yield
0.00%
Theravance Biopharma Inc. Ordinary Shares in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Theravance Biopharma sells ViBativ and Trelegy-royalty-linked revenue streams, and develops oral and inhaled therapeutics, with its own pipeline sitting on top of a legacy commercial base. The company's edge is a 75.1% gross margin, which tells you the product mix is high-value even as the top line shrinks. Revenue fell 20.9% year on year, so the investment case rests on the margin structure holding while the sales base is reshaped, rather than on any near-term acceleration. At $884M market cap and a forward P/E of 9.7 against a trailing 16.4, the market is pricing in earnings improvement, with an operating margin of 8.9% suggesting that improvement has not yet arrived in full. The name is worth a deeper look if the portfolio team wants exposure to a shrinking-revenue, high-gross-margin biotech with a composite score of 59/100 and no index membership to anchor flows.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
high
Revenue shrinking sharply
Revenue is down 20.9% year over year, while the 5-year revenue CAGR is +8.4%. Earnings are flat YoY at 0.0%, so the decline is not yet reaching the bottom line.
moderate
Score down 8 points in 90 days
The ACCE score fell from 66 to 58 over 90 days, with Momentum at 54 and Growth at 7 the weakest components. The price sits 2.7% below the ACCE price target of $17.50, so the score weakness is not a valuation signal.
moderate
Insider selling without buys
Insiders disclosed $6.36M in sales across the last 10 filings and zero buys. Insider ownership is only 4.6%, so the selling is modest in relative terms but one-directional.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Sep 25, 2026
Why it could do well
Free cash flow over the last twelve months reached $238M, a cash generation figure that matters for a company of this size.
Return on invested capital of 23.3% shows the business earns strong returns on the money put into it.
At a forward P/E of 9.7x, the stock trades well below the sector median forward P/E of 24.1x.
Why it could disappoint
Revenue fell 20.9% year over year, a sharp reversal from a five-year average growth rate of 8.4% per year.
Latest earnings per share came in 50.0% below expectations, with 0.07 reported against 0.14 expected.
Only 50% of analysts rate the shares Buy or Strong Buy, and the diluted share count rose 5.4% last fiscal year.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TBPH's valuation models land
Price
$17.03
Model fair value
$17.33
Model range
$5.06 to $30.50
Fair value $17.33
Price $17.03
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores